188 related articles for article (PubMed ID: 22619523)
1. Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS.
Ding XY; Hong CJ; Liu Y; Gu ZL; Xing KL; Zhu AJ; Chen WL; Shi LS; Zhang XN; Zhang Q
Int J Nanomedicine; 2012; 7():1723-35. PubMed ID: 22619523
[TBL] [Abstract][Full Text] [Related]
2. Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption.
Bei YY; Chen XY; Liu Y; Xu JY; Wang WJ; Gu ZL; Xing KL; Zhu AJ; Chen WL; Shi LS; Wang Q; Zhang XN; Zhang Q
Int J Nanomedicine; 2012; 7():1819-27. PubMed ID: 22619530
[TBL] [Abstract][Full Text] [Related]
3. Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers.
Guan M; Zhu QL; Liu Y; Bei YY; Gu ZL; Zhang XN; Zhang Q
Int J Nanomedicine; 2012; 7():1921-30. PubMed ID: 22605938
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice.
Liu MC; Ma XQ; Xu Y; Peng LH; Han M; Gao JQ
J Pharm Biomed Anal; 2016 Feb; 119():76-83. PubMed ID: 26658337
[TBL] [Abstract][Full Text] [Related]
5. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy.
Guan M; Zhou Y; Zhu QL; Liu Y; Bei YY; Zhang XN; Zhang Q
Nanomedicine; 2012 Oct; 8(7):1172-81. PubMed ID: 22321383
[TBL] [Abstract][Full Text] [Related]
6. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Wang Q; Zhang L; Hu W; Hu ZH; Bei YY; Xu JY; Wang WJ; Zhang XN; Zhang Q
Nanomedicine; 2010 Apr; 6(2):371-81. PubMed ID: 19699319
[TBL] [Abstract][Full Text] [Related]
7. An investigation on liver-targeting microemulsions of norcantharidin.
Zhang L; Sun X; Zhang ZR
Drug Deliv; 2005; 12(5):289-95. PubMed ID: 16188728
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of an LC-ESI-MS/MS approach to determine a highly hydrophobic drug, norcantharidin palmitate, and apply to a preliminary pharmacokinetic study in rats.
Liu X; Tao X; Zheng Q; Xu H; Zhang Y; Lei T; Yin T; He H; Tang X
Biomed Chromatogr; 2017 Dec; 31(12):. PubMed ID: 28500645
[TBL] [Abstract][Full Text] [Related]
9. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
10. Studies on anti-hepatocarcinoma effect, pharmacokinetics and tissue distribution of carboxymethyl chitosan based norcantharidin conjugates.
Chi J; Jiang Z; Chen X; Peng Y; Liu W; Han B; Han B
Carbohydr Polym; 2019 Dec; 226():115297. PubMed ID: 31582090
[TBL] [Abstract][Full Text] [Related]
11. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
12. [Studies on the liver targeting of norcantharindin microemulsion].
Zhang L; Xiang D; Hong Z; Zhang ZR
Yao Xue Xue Bao; 2004 Aug; 39(8):650-5. PubMed ID: 15563071
[TBL] [Abstract][Full Text] [Related]
13. Separation and identification of norcantharidin metabolites in vivo by GC-MS method.
Wei C; Teng Y; Wang B; Zhang X; Yuan G; Liu X; Li R; Guo R
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(20):1741-7. PubMed ID: 21565566
[TBL] [Abstract][Full Text] [Related]
14. Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment.
Li M; Xu X; Lu F; Guo S
Drug Deliv; 2014 Jun; 21(4):293-301. PubMed ID: 24156408
[TBL] [Abstract][Full Text] [Related]
15. A highly stable norcantharidin loaded lipid microspheres: preparation, biodistribution and targeting evaluation.
Ma J; Teng H; Wang J; Zhang Y; Ren T; Tang X; Cai C
Int J Pharm; 2014 Oct; 473(1-2):475-84. PubMed ID: 25089504
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, in vitro and in vivo evaluation of new norcantharidin-conjugated hydroxypropyltrimethyl ammonium chloride chitosan derivatives as polymer therapeutics.
Xu X; Li Y; Wang F; Lv L; Liu J; Li M; Guo A; Jiang J; Shen Y; Guo S
Int J Pharm; 2013 Sep; 453(2):610-9. PubMed ID: 23742972
[TBL] [Abstract][Full Text] [Related]
17. Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry.
Liu M; Ma X; Jin Z; Li W; Guo M; Li F
Anal Bioanal Chem; 2013 Nov; 405(28):9273-83. PubMed ID: 24096565
[TBL] [Abstract][Full Text] [Related]
18. Application of an ultra-performance liquid chromatography method with tandem mass spectrometry to pharmacokinetics, tissue distribution and excretion in the study of DAT-230, a novel tubulin-binding agent candidate, in rats.
Tang J; Zhang C; Sun J; Zhao L; Zhang W; Liu Z; Sun L; Chen X
J Pharm Biomed Anal; 2015 Jun; 110():49-57. PubMed ID: 25800882
[TBL] [Abstract][Full Text] [Related]
19. Rutin-encapsulated chitosan nanoparticles targeted to the brain in the treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Naqvi AA; Alam MA; Ashafaq M; Samim M; Iqbal Z; Ahmad FJ
Int J Biol Macromol; 2016 Oct; 91():640-55. PubMed ID: 27264648
[TBL] [Abstract][Full Text] [Related]
20. Preparation and pharmacological evaluation of norcantharidin-conjugated carboxymethyl chitosan in mice bearing hepatocellular carcinoma.
Jiang Z; Chi J; Han B; Liu W
Carbohydr Polym; 2017 Oct; 174():282-290. PubMed ID: 28821069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
